Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia

Intermittent hypoxia (IH) is associated with increased endothelial dysfunction and cardiovascular disorders. Exosomes released in biological fluids may act as vehicles for propagating such damage, modifying the functional phenotype of endothelial cells. Drug interventions, however, may provide prote...

Full description

Bibliographic Details
Main Authors: Abdelnaby Khalyfa, Nina Youssefnia, Glen E. Foster, Andrew E. Beaudin, Zhuanghong Qiao, Vincent Pialoux, Matiram Pun, Patrick J. Hanly, Leila Kheirandish-Gozal, Marc J. Poulin, David Gozal
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-12-01
Series:Frontiers in Neurology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fneur.2017.00709/full
id doaj-d1178464d20b4ec8974dc03120cc2cd1
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Abdelnaby Khalyfa
Nina Youssefnia
Glen E. Foster
Glen E. Foster
Andrew E. Beaudin
Andrew E. Beaudin
Zhuanghong Qiao
Vincent Pialoux
Vincent Pialoux
Matiram Pun
Matiram Pun
Patrick J. Hanly
Patrick J. Hanly
Leila Kheirandish-Gozal
Marc J. Poulin
Marc J. Poulin
Marc J. Poulin
Marc J. Poulin
Marc J. Poulin
David Gozal
spellingShingle Abdelnaby Khalyfa
Nina Youssefnia
Glen E. Foster
Glen E. Foster
Andrew E. Beaudin
Andrew E. Beaudin
Zhuanghong Qiao
Vincent Pialoux
Vincent Pialoux
Matiram Pun
Matiram Pun
Patrick J. Hanly
Patrick J. Hanly
Leila Kheirandish-Gozal
Marc J. Poulin
Marc J. Poulin
Marc J. Poulin
Marc J. Poulin
Marc J. Poulin
David Gozal
Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia
Frontiers in Neurology
cardiovascular disease
intermittent hypoxia
sleep apnea
experimental human model
endothelium
exosomes
author_facet Abdelnaby Khalyfa
Nina Youssefnia
Glen E. Foster
Glen E. Foster
Andrew E. Beaudin
Andrew E. Beaudin
Zhuanghong Qiao
Vincent Pialoux
Vincent Pialoux
Matiram Pun
Matiram Pun
Patrick J. Hanly
Patrick J. Hanly
Leila Kheirandish-Gozal
Marc J. Poulin
Marc J. Poulin
Marc J. Poulin
Marc J. Poulin
Marc J. Poulin
David Gozal
author_sort Abdelnaby Khalyfa
title Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia
title_short Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia
title_full Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia
title_fullStr Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia
title_full_unstemmed Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia
title_sort plasma exosomes and improvements in endothelial function by angiotensin 2 type 1 receptor or cyclooxygenase 2 blockade following intermittent hypoxia
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2017-12-01
description Intermittent hypoxia (IH) is associated with increased endothelial dysfunction and cardiovascular disorders. Exosomes released in biological fluids may act as vehicles for propagating such damage, modifying the functional phenotype of endothelial cells. Drug interventions, however, may provide protection for the endothelium, in spite of exosomal activity. Using an experimental human model of IH, we investigated whether the beneficial effects of two drugs, celecoxib (CEL) and losartan (LOS), on IH-induced vascular dysfunction was mediated via exosomes or independent of IH-induced exosomal cargo alterations. We hypothesized that the beneficial effects of CEL and LOS on IH-induced vascular dysfunction would be mediated via modifications of exosomal properties by the drugs, rather than by direct effects of the drugs on the endothelium. Ten male volunteers were exposed to IH (single exposure of 6 h) while receiving LOS, CEL, or placebo (P) for 4 days before IH exposures, and plasma samples were obtained from which exosomes were isolated, and incubated with naïve human endothelial cell cultures either not treated or pretreated with LOS, CEL, or P. Functional reporter assays (monolayer impedance, monocyte adhesion, and eNOS phosphorylation) revealed that the degree of exosome-induced endothelial dysfunction was similar among IH-exposed subjects independent of drug treatment. However, pretreatment of naïve endothelial cells with LOS or CEL before addition of exosomes from IH-exposed subjects afforded significant protection. Thus, the cardiovascular protective impact of LOS and CEL appears to be mediated by their direct effects on endothelial cells, rather than via modulation of exosomal cargo.
topic cardiovascular disease
intermittent hypoxia
sleep apnea
experimental human model
endothelium
exosomes
url http://journal.frontiersin.org/article/10.3389/fneur.2017.00709/full
work_keys_str_mv AT abdelnabykhalyfa plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT ninayoussefnia plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT glenefoster plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT glenefoster plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT andrewebeaudin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT andrewebeaudin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT zhuanghongqiao plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT vincentpialoux plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT vincentpialoux plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT matirampun plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT matirampun plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT patrickjhanly plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT patrickjhanly plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT leilakheirandishgozal plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT marcjpoulin plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
AT davidgozal plasmaexosomesandimprovementsinendothelialfunctionbyangiotensin2type1receptororcyclooxygenase2blockadefollowingintermittenthypoxia
_version_ 1725705138442600448
spelling doaj-d1178464d20b4ec8974dc03120cc2cd12020-11-24T22:40:16ZengFrontiers Media S.A.Frontiers in Neurology1664-22952017-12-01810.3389/fneur.2017.00709324689Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent HypoxiaAbdelnaby Khalyfa0Nina Youssefnia1Glen E. Foster2Glen E. Foster3Andrew E. Beaudin4Andrew E. Beaudin5Zhuanghong Qiao6Vincent Pialoux7Vincent Pialoux8Matiram Pun9Matiram Pun10Patrick J. Hanly11Patrick J. Hanly12Leila Kheirandish-Gozal13Marc J. Poulin14Marc J. Poulin15Marc J. Poulin16Marc J. Poulin17Marc J. Poulin18David Gozal19Section of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesSection of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaSection of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaDepartment of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaSection of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, CanadaDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCumming School of Medicine, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, CanadaFaculty of Kinesiology, University of Calgary, Calgary, AB, CanadaSection of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL, United StatesIntermittent hypoxia (IH) is associated with increased endothelial dysfunction and cardiovascular disorders. Exosomes released in biological fluids may act as vehicles for propagating such damage, modifying the functional phenotype of endothelial cells. Drug interventions, however, may provide protection for the endothelium, in spite of exosomal activity. Using an experimental human model of IH, we investigated whether the beneficial effects of two drugs, celecoxib (CEL) and losartan (LOS), on IH-induced vascular dysfunction was mediated via exosomes or independent of IH-induced exosomal cargo alterations. We hypothesized that the beneficial effects of CEL and LOS on IH-induced vascular dysfunction would be mediated via modifications of exosomal properties by the drugs, rather than by direct effects of the drugs on the endothelium. Ten male volunteers were exposed to IH (single exposure of 6 h) while receiving LOS, CEL, or placebo (P) for 4 days before IH exposures, and plasma samples were obtained from which exosomes were isolated, and incubated with naïve human endothelial cell cultures either not treated or pretreated with LOS, CEL, or P. Functional reporter assays (monolayer impedance, monocyte adhesion, and eNOS phosphorylation) revealed that the degree of exosome-induced endothelial dysfunction was similar among IH-exposed subjects independent of drug treatment. However, pretreatment of naïve endothelial cells with LOS or CEL before addition of exosomes from IH-exposed subjects afforded significant protection. Thus, the cardiovascular protective impact of LOS and CEL appears to be mediated by their direct effects on endothelial cells, rather than via modulation of exosomal cargo.http://journal.frontiersin.org/article/10.3389/fneur.2017.00709/fullcardiovascular diseaseintermittent hypoxiasleep apneaexperimental human modelendotheliumexosomes